LSD1 is over-expressed in many cancers and a range of inhibitors targeting LSD1 have been developed based on a small molecular weight compound (TCP tranylcypromine), originally approved for treatment of anxiety disorders, see Figure 3. Here, KDM1A is linked to cancer.